SciBase raises SEK 120 million ($18 million)

SciBase has recently closed a financing round of SEK 120 million ($18 million), to be divided in two tranches. The funds will finance the company through the ongoing market introduction in Europe/Australia as well as the regulatory approval process and subsequent launch in the US. The financing round was secured in a combination of current and new investors including Swedish based SEB Venture Capital, SEB Pensionsstiftelse, Fouriertransform as well as London based Omega Funds. “We are very pleased with the outcome of the financing round. This long-term investment will enable the company to provide continuous market support in order to meet the demand for Nevisense” says SciBase’s CEO, Anders Lundqvist and continues “This unique product allows clinicians to make more informed clinical decisions when evaluating suspicious lesions, thus potentially save lives”.